Author:
Yu Lawrence X.,Baker Jeffrey,Berlam Susan C.,Boam Ashley,Brandreth E. J.,Buhse Lucinda,Cosgrove Thomas,Doleski David,Ensor Lynne,Famulare Joseph,Ganapathy Mohan,Grampp Gustavo,Hussong David,Iser Robert,Johnston Gordon,Kesisoglou Filippos,Khan Mansoor,Kozlowski Steven,Lacana Emanuela,Lee Sau L.,Miller Stephen,Miksinski Sarah Pope,Moore Christine M. V.,Mullin Theresa,Raju G. K.,Raw Andre,Rosencrance Susan,Rosolowsky Mark,Stinavage Paul,Thomas Hayden,Wesdyk Russell,Windisch Joerg,Vaithiyalingam Sivakumar
Publisher
Springer Science and Business Media LLC
Reference24 articles.
1. U. S. Food and Drug Administration. Final report on pharmaceutical cGMPs for the 21st century—a risk-based approach. 2004.
2. U. S. Food and Drug Administration. Guidance for industry: PAT—a framework for innovative pharmaceutical development, manufacturing, and quality assurance. 2004.
3. U. S. Food and Drug Administration. Guidance for industry: Q8(2) pharmaceutical development. 2009.
4. U. S. Food and Drug Administration. Guidance for industry: Q9 quality risk management. 2006.
5. U. S. Food and Drug Administration. Guidance for industry: Q10 pharmaceutical quality system. 2009.
Cited by
15 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Artificial intelligence in drug discovery and clinical practice;From Current to Future Trends in Pharmaceutical Technology;2024
2. Industry 4.0 for pharmaceutical manufacturing: Preparing for the smart factories of the future;International Journal of Pharmaceutics;2021-06
3. Index;Perfusion Cell Culture Processes for Biopharmaceuticals;2020-08-06
4. Mechanistic and Statistical Modelling of Bioprocesses;Perfusion Cell Culture Processes for Biopharmaceuticals;2020-08-06
5. Clinical- and Commercial-Scale Reactors;Perfusion Cell Culture Processes for Biopharmaceuticals;2020-08-06